Clinical Trial Update: Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment [Phase 4]

View source ↗

Summary

Phase 4 trial of rivastigmine for cognitive impairment in multiple sclerosis was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rivastigmine (Rivastigmine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis, Cognitive Impairment | Phase 4 | Status: TERMINATED | Results posted: 2012-02-24